News in brief: 17-fold risk of infection with proteosome inhibitors in myeloma: Hybrid ISTH 2021 abandoned; Screen for latent infection in OS-born cancer patients

Infection risk with new myeloma agents Proteosome inhibitors (PIs) and multiple lines of therapy are associated with a higher risk of infections in patients with multiple myeloma (MM). A Melbourne study identified 345 infections in a cohort of 148 patients with MM treated with second-generation therapies and/or monoclonal antibodies between January 2013 and December 2018. ...

Already a member?

Login to keep reading.

© 2021 the limbic